NY-ESO-1

New York esophageal squamous cell carcinoma antigen-1 · Immune Design (a Merck subsidiary)

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NY-ESO-1, covering 2017-08-17 to 2020-07-09. Get the full timeline:

Most recent: Clinical Trial Update: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma [Phase 1]

See pricing